Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

ALSUntangled supports further study of cannabis and cannabinoids in ALS

Original source

CannabisALSUntangled · 28 May 2012 (opens in a new tab)

ALSUntangled said cannabis and its active ingredients, cannabinoids, should be studied further in amyotrophic lateral sclerosis (ALS). The review cited biological mechanisms, limited animal studies and anecdotal reports of symptom relief, but did not establish that cannabis slows ALS or treats its symptoms.

Why this matters

This may guide research into controlled studies of cannabis or cannabinoids for ALS. It does not change treatment for people with ALS because the cited evidence comes from small, non-randomized, unblinded animal studies and anecdotal reports rather than a controlled clinical trial.

Limitations and context

This is an independent expert review published in 2012, not a new clinical trial. The review described limited animal evidence and anecdotal reports, and proposed a small controlled case series; it did not report results from such a study.

Summarised by Compass 10 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?